Gene-targeted olaparib proves effective against prostate cancer

The gene-targeting drug olaparib, marketed under the name Lynparza and already used for breast and ovarian cancer, was effective at slowing disease progression in more than 80 percent of men with prostate cancer.
Source: Health News - UPI.com - Category: Consumer Health News Source Type: news

Related Links:

A pioneering precision medicine already licensed for breast and ovarian cancer can also slow or stop tumour growth in some men with advanced prostate cancer, a new clinical trial shows. The phase II trial found that over 80 per cent of men with prostate cancer whose tumours had mutations in the BRCA genes responded well to treatment with the targeted drug olaparib.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
This study is registered with PROSPERO, CRD42018114781.Findings47 publications provided data from 46 samples including 4 717 839 individuals (501 559 patients with mental illness, and 4 216 280 controls), of whom 69·85% were women, for screening for breast cancer (k=35; 296 699 individuals with mental illness, 1 023 288 in the general population), cervical cancer (k=29; 295 688 with mental illness, 3 540 408 in general population), colorectal cancer (k=12; 153 283 with mental illness, 2 228 966 in general population), lung and gastric cancer (both k=1; 420 with mental illness, none in gener...
Source: The Lancet Psychiatry - Category: Psychiatry Source Type: research
We present a unique case of OMS related to a stage IIIC high grade serous ovarian carcinoma in a patient with germline BRCA2 mutation, with ten years of clinical follow up. This case report is presented to document the rare association of OMS with epithelial ovarian cancer. Additionally, in this case, OMS and epithelial cancer were successfully treated with medical therapy alone. This is the first report to our knowledge to document ten years of clinical follow up in this context, and to report that the association may not be evident at the time of ovarian cancer recurrence.
Source: Gynecologic Oncology Reports - Category: OBGYN Source Type: research
Authors: Brenner DR, Ruan Y, Shaw E, O'Sullivan D, Poirier AE, Heer E, Villeneuve PJ, Walter SD, Friedenreich CM, Smith L, De P Abstract BACKGROUND: Although cancer incidence over time is well documented in Canada, trends by birth cohort and age group are less well known. We analyzed age- and sex-standardized incidence trends in Canada for 16 major cancer sites and all cancers combined. METHODS: We obtained nationally representative population-based cancer incidence data in Canada between 1971 and 2015 from the National Cancer Incidence Reporting System (1969-1992) and the Canadian Cancer Registry (1992-2015). ...
Source: Canadian Medical Association Journal - Category: General Medicine Tags: CMAJ Source Type: research
The proteasome deubiquitinase inhibitor bAP15 downregulates TGF-β/Smad signaling and induces apoptosis via UCHL5 inhibition in ovarian cancer. Oncotarget. 2019 Oct 15;10(57):5932-5948 Authors: Fukui S, Nagasaka K, Miyagawa Y, Kikuchi-Koike R, Kawata Y, Kanda R, Ichinose T, Sugihara T, Hiraike H, Wada-Hiraike O, Sasajima Y, Ayabe T Abstract The ubiquitin-proteasome pathway plays an important role in the regulation of cellular proteins. As an alternative to the proteasome itself, recent research has focused on methods to modulate the regulation of deubiquitinating enzymes (DUBs) upstream of the prot...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Researchers at Georgia Institute of Technology (Georgia Tech) are working on a method that could enable rapid and low-cost separation of tumor cells circulating in the bloodstream. The researchers developed the new approach using 3D-printed cell traps, Georgia Tech's research news team reported. According to the researchers, trapping the white blood cells – which are about the size of cancer cells – and filtering out smaller red blood cells leaves behind the tumor cells, which could then be used to diagnose the disease, potentially provide early warning of recurrence and enable research ...
Source: MDDI - Category: Medical Devices Authors: Tags: 3-D Printing Source Type: news
Al-Dayel F, Al-Kuraya KS Abstract Sanger Sequencing and immunohistochemistry was employed to investigate the TERT promoter mutations and TERT protein expression with their association to clinicopathological characteristics in over 2200 samples of Middle Eastern origin from 13 different types of cancers. The TERT promoter mutations were most frequently present in bladder cancer (68.6%), followed by central nervous system tumors (28.7%), thyroid cancer (15.4%), prostate cancer (9.3%), endometrial carcinoma (3.7%), rhabdomyosarcoma (1.4%), colorectal cancer (1%), epithelial ovarian carcinoma (0.7%) and breast cancer ...
Source: Genomics - Category: Genetics & Stem Cells Authors: Tags: Genomics Source Type: research
Authors: Daly MB Abstract The National Comprehensive Cancer Network (NCCN) clinical practice guidelines have become the most recognized standard for clinical policy in cancer care. The Genetic Breast and Ovarian Guideline was introduced in 1999 with an emphasis on BRCA1/2. Based on evidence linking prostate cancer to the BRCA genes, prostate cancer was added to the guideline as a criterion for risk assessment in 2013. The current criteria include aggressive/metastatic disease and family history of BRCA-related cancers. PMID: 31629424 [PubMed - in process]
Source: Canadian Journal of Urology - Category: Urology & Nephrology Tags: Can J Urol Source Type: research
This study aimed to study the travel distance to cancer patient's GP and to the hospital of diagnosis and the association with tumour stage for 12 cancer types. A cohort study was conducted including cancer patients in Denmark diagnosed between 2005 and 2016 with rectum, malignant melanoma, breast, testis, oesophageal, colon, cervix, prostate, stomach, pancreatic, lung and ovary cancer (n = 256,663). Distance to each patient's GP and to the hospital of diagnosis were calculated using ArcGIS, Network Analyst. The results showed that for most easy-to-diagnose cancer types (rectum cancer, malignant melanoma, testis cancer...
Source: Health and Place - Category: Environmental Health Authors: Tags: Health Place Source Type: research
Abstract AP-1 is a dimeric complex that is composed of JUN, FOS, ATF and MAF protein families. FOS-related antigen 1 (FRA1) which encoded by FOSL1 gene, belongs to the FOS protein family, and mainly forms an AP-1 complex with the protein of the JUN family to exert an effect. Regulation of FRA1 occurs at levels of transcription and post-translational modification, and phosphorylation is the major post-translational modification. FRA1 is mainly regulated by the mitogen-activated protein kinases signaling pathway and is degraded by ubiquitin-independent proteasomes. FRA1 can affect biological functions, such as tumor...
Source: Molecular Biology Reports - Category: Molecular Biology Authors: Tags: Mol Biol Rep Source Type: research
More News: Cancer | Cancer & Oncology | Genetics | Health | Ovarian Cancer | Ovaries | Prostate Cancer